Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

News

August 16, 2023
PRESS RELEASE: On August 10, 2023, a new editorial was published in Oncotarget, entitled, “Inhibition of glutamine metabolism: acting on tumoral cells or on tumor microenvironment?” continue reading »

Peripheral Surrogates of Tumor Burden to Guide Therapeutic Strategies for HPV-Associated Malignancies

News

August 14, 2023
PRESS RELEASE: On August 10, 2023, a new review paper was published in Oncotarget, entitled, “Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies.” continue reading »

Whole-Genome Doubling and Aneuploidy in Human Cancer

Oncotarget

August 10, 2023
In a new editorial paper, researchers from Tel Aviv University discuss a recent study exploring how whole-genome doubling shapes the aneuploidy landscape of human cancers. continue reading »

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

News

August 9, 2023
PRESS RELEASE: On August 7, 2023, a new research perspective was published in Oncotarget, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.” continue reading »

AGO2 in T-prolymphocytic Leukemia (T-PLL)

News

August 7, 2023
PRESS RELEASE: On May 4, 2023, a new editorial was published in Oncotarget, entitled, “AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function.” continue reading »